Emergent BioSolutions to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

Emergent BioSolutions (NYSE: EBS) will report fourth quarter and full year 2025 financial results and host a conference call on Thursday, February 26, 2026 at 5:00 PM ET.

Rhea-AI Summary

Emergent BioSolutions (NYSE: EBS) will report fourth quarter and full year 2025 financial results and host a conference call on Thursday, February 26, 2026 at 5:00 PM ET.

Investors can join via live webcast on the company’s Investors page or by telephone after registering in advance; a replay will be posted on the Investors page.

Argus Feb 12 session

-1.63% close to close Open Argus

Details

News Market Reaction – EBS

In the Feb 12 session, EBS declined 1.63%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement sets a clear timetable for Emergent BioSolutions’ review of Q4 and full-year 2025 ...

Analysis

This announcement sets a clear timetable for Emergent BioSolutions’ review of Q4 and full-year 2025 results on February 26, 2026 at 5:00 pm ET. Investors can contextualize upcoming numbers against recent FDA approval, government contract wins, and debt reduction moves highlighted in prior releases. Key items to watch include balance sheet progress, operational performance across product lines, and any updated strategic commentary during the conference call webcast.

Key Figures

Earnings call date: February 26, 2026 Earnings call time: 5:00 pm ET Announcement date: February 12, 2026

Earnings call date

February 26, 2026

Scheduled Q4 and full-year 2025 results discussion

Earnings call time

5:00 pm ET

Start time of Q4 and full-year 2025 conference call

Announcement date

February 12, 2026

Date earnings-call press release was issued

Historical Context

5 past events · Latest: Jan 14

5 events

1. Jan 14

   Product approval

   24h Move

   +3.0%

   FDA approved supplemental NDA for new NARCAN® Nasal Spray carrying case.

2. Jan 12

   Debt reduction

   24h Move

   -4.4%

   Voluntary prepayment of $100 million on term loan, reducing gross debt.

3. Jan 08

   Government contract

   24h Move

   -3.0%

   Delivery order up to $21.5 million for BioThrax® anthrax vaccine supply.

4. Jan 08

   Clinical support

   24h Move

   -3.9%

   Additional backing for Africa CDC-led MOSA mpox study with no safety concerns.

5. Jan 07

   Conference presentation

   24h Move

   +5.7%

   Announcement of presentation at the 44th Annual J.P. Morgan Healthcare Conference.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

GAITHERSBURG, Md., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, February 26, 2026, at 5:00 pm eastern time to discuss the financial results for the fourth quarter and full year of 2025.

Participants can access the conference call live via webcast and also by visiting the Investors page of Emergent’s website. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call.

A replay of the call can be accessed from the Investors page of Emergent’s website.

About Emergent BioSolutions
At Emergent, our mission is to protect and save lives. For over 25 years, we’ve been at work preparing those entrusted with protecting public health. We deliver protective and life-saving solutions for health threats like smallpox, mpox, botulism, Ebola, anthrax and opioid overdose emergencies. To learn more about how we help prepare communities around the world for today’s health challenges and tomorrow’s threats, visit our website and follow us on LinkedIn, X, Instagram, Apple Podcasts and Spotify.

Investor Contact:
Richard S. Lindahl
Executive Vice President, CFO
lindahlr@ebsi.com  

Media Contact:
Assal Hellmer
Vice President, Communications
mediarelations@ebsi.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Emergent BioSolutions (EBS) report Q4 and full year 2025 results and hold the conference call?

The conference call is scheduled for Thursday, February 26, 2026 at 5:00 PM ET. According to Emergent BioSolutions, the call will review fourth quarter and full year 2025 financial results and related commentary.

How can investors access the Emergent BioSolutions (EBS) February 26, 2026 conference call?

Investors can access the call via live webcast on the company’s Investors page or by telephone after registering. According to Emergent BioSolutions, webcast and telephone options will both be available for participants.

What is required to join the Emergent BioSolutions (EBS) conference call by telephone on February 26, 2026?

Telephone participants must register in advance to receive dial-in details and a unique passcode. According to Emergent BioSolutions, registrants will get a confirmation email with dial-in number, passcode, and registrant ID.

Will there be a replay of the Emergent BioSolutions (EBS) February 26, 2026 earnings call?

Yes, a replay will be available on the company’s Investors page after the live call. According to Emergent BioSolutions, investors can access the archived webcast from the Investors page.

Where can I find registration and dial-in information for the Emergent BioSolutions (EBS) earnings call?

Registration and dial-in details are provided via the company’s registration link and confirmation email. According to Emergent BioSolutions, telephone registrants will receive exact dial-in instructions and a unique passcode.